Posted in | News | Medical Optics

Leica and Visiopharm Create Integrated Digital Pathology Solution

Leica Microsystems, world-leading providers of Total Digital Pathology solutions, and Visiopharm the leading provider of Histoinformatics Solutions for Life-Sciences, today announce the completed integration of Leica’s SlidePath Digital Image Hub with Visiopharm’s Whole-Slide InformaticsTM solutions for Digital Pathology.

Users can now take advantage of superior image capture and management from Leica Microsystems and excellent Whole Slide image analysis and Whole Slide Stereology from Visiopharm in a single system.

This integration provides a truly streamlined workflow for customers using image analysis and stereology in digital pathology. All images stored on the Digital Image Hub server can be browsed and accessed via the Visiopharm software. Selected images are then easily opened and analyzed by either Visiopharm’s image analysis software or stereology software. Following analysis, users can quickly view the resulting data and associated slides through the Visiopharm software interface.

Leica’s Digital Image Hub, developed by SlidePath, is a scalable enterprise-level solution for the management and archiving of digital slides and associated data. As Digital Image Hub is accessed via a standard internet browser and supports images from a variety of digital slide scanners, it is the perfect partner for Visiopharm’s whole slide analysis solutions.

Stavanger University Hospital have chosen Leica Microsystems’ Total Digital Pathology solution for scanning and storage of digital slides, and the Visiopharm solution for image analysis.

Dr. Kjell H Kjellevold, Head of the Pathology Department says, “For us, the combination of these two systems is ideal. The speed and image quality of the Leica SCN400 slide scanner combined with the Digital Image Hub management solution is exactly what is required for making Digital Pathology feasible for research work. The image analysis software from Visiopharm consolidates simplicity for routine work and the flexibility for research. This, together with the low costs of learning and computation, was critical for our decision”.

While Leica Microsystems will continue to develop and expand their existing range of Digital Pathology image analysis solutions, including Tissue IA and the Ariol system, the integration with Visiopharm gives additional options to customers, enabling them to choose the analysis solution that is right for their needs.

Visiopharm will continue to consolidate and expand its integration to the leading slide databases on the Digital Pathology market.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Leica Microsystems GmbH. (2019, February 28). Leica and Visiopharm Create Integrated Digital Pathology Solution. AZoOptics. Retrieved on November 23, 2024 from https://www.azooptics.com/News.aspx?newsID=14262.

  • MLA

    Leica Microsystems GmbH. "Leica and Visiopharm Create Integrated Digital Pathology Solution". AZoOptics. 23 November 2024. <https://www.azooptics.com/News.aspx?newsID=14262>.

  • Chicago

    Leica Microsystems GmbH. "Leica and Visiopharm Create Integrated Digital Pathology Solution". AZoOptics. https://www.azooptics.com/News.aspx?newsID=14262. (accessed November 23, 2024).

  • Harvard

    Leica Microsystems GmbH. 2019. Leica and Visiopharm Create Integrated Digital Pathology Solution. AZoOptics, viewed 23 November 2024, https://www.azooptics.com/News.aspx?newsID=14262.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.